Heidi H Gillenwater

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
  2. ncbi A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
  3. ncbi Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
  4. ncbi Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
  5. ncbi Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB #7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
  6. ncbi Treatment options for small cell lung cancer
    Todd Wolf
    Division of Hematology and Oncology, University of Virginia, Box 800716, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Curr Oncol Rep 6:268-71. 2004
  7. ncbi Second-line treatment of small-cell lung cancer
    Cecilia MacCallum
    Division of Hematology and Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Curr Oncol Rep 8:258-64. 2006
  8. ncbi Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion
    David R Jones
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908 0679, USA
    J Thorac Oncol 5:75-81. 2010
  9. ncbi Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Gary M Strauss
    Tufts Medical Center, Division of Medical Oncology, Tufts NEMC, Boston, MA 02111, USA
    J Clin Oncol 26:5043-51. 2008
  10. ncbi Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Thomas A Hensing
    Kellogg Cancer Center, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Anticancer Drugs 17:697-704. 2006

Detail Information

Publications10

  1. ncbi A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
    ....
  2. ncbi A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  3. ncbi Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  4. ncbi Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
    ..This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC)...
  5. ncbi Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB #7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
    ..05). CONCLUSIONS: Gemcitabine plasma pharmacokinetic parameters are significantly altered in the presence of paclitaxel...
  6. ncbi Treatment options for small cell lung cancer
    Todd Wolf
    Division of Hematology and Oncology, University of Virginia, Box 800716, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Curr Oncol Rep 6:268-71. 2004
    ..This trial may change the standard of care for patients with extensive-stage disease. A similar ongoing trial in the United States is attempting to confirm these results...
  7. ncbi Second-line treatment of small-cell lung cancer
    Cecilia MacCallum
    Division of Hematology and Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Curr Oncol Rep 8:258-64. 2006
    ..Combination therapies have also been investigated, and some have been shown to increase activity over single agents, but toxicity and quality of life variables are imperative in the treatment of this patient population...
  8. ncbi Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion
    David R Jones
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908 0679, USA
    J Thorac Oncol 5:75-81. 2010
    ..This dose escalation phase I study was designed to determine the maximum tolerated dose of intrapleural docetaxel administered through an implantable catheter in subjects with MPE...
  9. ncbi Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Gary M Strauss
    Tufts Medical Center, Division of Medical Oncology, Tufts NEMC, Boston, MA 02111, USA
    J Clin Oncol 26:5043-51. 2008
    ..This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC...
  10. ncbi Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Thomas A Hensing
    Kellogg Cancer Center, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Anticancer Drugs 17:697-704. 2006
    ..The lack of activity in either patient subgroup, however, does not support further evaluation of this drug as a single agent in this disease...